Skip to main content
MLTX
NASDAQ Life Sciences

Sonelokimab Clears All Phase 3 PsA Hurdles; MoonLake's Cash Runway Extends to Mid-2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$18.64
Mkt Cap
$1.536B
52W Low
$5.95
52W High
$62.75
52W Position info
213% above low
Off High info
70% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MLTX has more than doubled off its 52-week low of $5.95.

Summary

Sonelokimab hit all endpoints in the Phase 3 IZAR-1 psoriatic arthritis trial, posting a 42.1% ACR50 response with clean safety. MoonLake's $537M cash balance funds operations to mid-2028.


Key Events · Product Development and Regulatory · MLTX

  • Phase 3 IZAR-1 Trial Met All Endpoints

    In bio-naïve psoriatic arthritis patients at Week 16, the 60 mg dose of sonelokimab delivered a 42.1% ACR50 response on the primary endpoint, with strong secondary outcomes: ACR20 66.5%, MDA 41.2%, and PASI90 61%.

  • Clean Safety Profile Maintained

    A blinded safety analysis revealed no new signals, consistent with prior studies, reinforcing sonelokimab's potential as a leading PsA treatment.

  • Strong Financial Position

    Q2 2026 cash and equivalents totaled $537.0M, and up to $400M remains available through a Hercules Capital debt facility, extending the cash runway to mid-2028.

  • Upcoming Catalysts

    Key milestones ahead: HS BLA submission expected by end of September 2026; IZAR-2 enrollment completion in Q3 2026; full IZAR-1 readout in H1 2027; and P-OLARIS results late 2026 or early 2027.


Analysis · MLTX · Life Sciences

The Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis met every primary and secondary endpoint, delivering robust efficacy across multiple disease domains. An ACR50 response of 42.1%, combined with high rates of skin clearance (PASI90 61%) and minimal disease activity (MDA 41.2%), positions sonelokimab as a potential best-in-class therapy in a multi-billion dollar market. The safety profile remains clean, with no new signals. With $537 million in cash and a debt facility providing up to $400 million in non-dilutive capital, MoonLake has a clear path to mid-2028—well beyond key catalysts including the HS BLA submission in September 2026 and the IZAR-2 readout. This derisks the PsA program and significantly expands the commercial opportunity beyond hidradenitis suppurativa.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLTX was trading at $18.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $5.95 to $62.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLTX - Latest Insights

MLTX
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $11.07 info
Change: -$0.530 (-5%) info
Market Cap: $942.131M info
MLTX
Nov 04, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.62
Real-time Price: $11.07 info
Change: -$0.550 (-5%) info
Market Cap: $942.131M info
MLTX
Nov 04, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $11.07 info
Change: -$0.540 (-5%) info
Market Cap: $942.131M info
MLTX
Sep 30, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.81
Real-time Price: $11.07 info
Change: -$0.7407 (-6%) info
Market Cap: $942.131M info
MLTX
Aug 10, 2026, 1:21 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $17.11
Real-time Price: $11.07 info
Change: -$6.04 (-35%) info
Market Cap: $942.131M info